Consideration of capacity and anesthesia range of ropivacaine in Serratus Plane Block

Consideration of capacity and anesthesia range of ropivacaine in Serratus Plane Block - Consideration of capacity and anesthesia range of ropivacaine in Serratus Plane Block

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016549

Enrollment

Registered

2015-02-16

Start date

2015-02-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

The administration of 0.375% ropivacaine of 20ml in Serratus Plane Block The administration of 0.375% ropivacaine of 40ml in Serratus Plane Block

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1,ASA-PS:1 or 2 2,Breast cancer surgery

Exclusion criteria

Exclusion criteria: 1,Can not be obtained the consent and cooperation 2,Allergies to use drugs 3,Weighing less than 50kg 4,BMI is 35 or more 5,Liver disease 6,Renal disease 7,Arrhythmia 8,Opioid addiction history 9,Chronic pain disease 10,Neuromuscular disease 11,Pregnant woman

Design outcomes

Primary

Measure	Time frame
Loss of cold and pain sensation area after the enforcement the Serratus Plane Block	—

Countries

Japan

Contacts

Public ContactKunigou Tatsuya

Obihiro Kosei Hospital Anesthesiology

tatsuya_9250@yahoo.co.jp0155-24-4161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026